These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 22771190)
1. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Handattu SP; Mishra VK; Anantharamaiah GM Atherosclerosis; 2012 Oct; 224(2):326-31. PubMed ID: 22771190 [TBL] [Abstract][Full Text] [Related]
2. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Handattu SP; Nayyar G; Garber DW; Palgunachari MN; Monroe CE; Keenum TD; Mishra VK; Datta G; Anantharamaiah GM Atherosclerosis; 2013 Mar; 227(1):58-64. PubMed ID: 23159231 [TBL] [Abstract][Full Text] [Related]
3. Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects. Nayyar G; Handattu SP; Monroe CE; Chaddha M; Datta G; Mishra VK; Keenum TD; Palgunachari MN; Garber DW; Anantharamaiah GM Atherosclerosis; 2010 Dec; 213(2):449-57. PubMed ID: 21030022 [TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice: a commentary. Reardon CA Atherosclerosis; 2012 Nov; 225(1):39-40. PubMed ID: 23040866 [No Abstract] [Full Text] [Related]
5. Anti-inflammatory and recycling properties of an apolipoprotein mimetic peptide, Ac-hE18A-NH(2). Datta G; White CR; Dashti N; Chaddha M; Palgunachari MN; Gupta H; Handattu SP; Garber DW; Anantharamaiah GM Atherosclerosis; 2010 Jan; 208(1):134-41. PubMed ID: 19656510 [TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report. Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696 [TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A. Sharifov OF; Nayyar G; Ternovoy VV; Palgunachari MN; Garber DW; Anantharamaiah G; Gupta H Innate Immun; 2014 Nov; 20(8):867-80. PubMed ID: 24323453 [TBL] [Abstract][Full Text] [Related]
9. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Li X; Chyu KY; Faria Neto JR; Yano J; Nathwani N; Ferreira C; Dimayuga PC; Cercek B; Kaul S; Shah PK Circulation; 2004 Sep; 110(12):1701-5. PubMed ID: 15353488 [TBL] [Abstract][Full Text] [Related]
10. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147 [TBL] [Abstract][Full Text] [Related]
11. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Wagner AC; Hama S; Hough G; Bachini E; Garber DW; Mishra VK; Palgunachari MN; Fogelman AM Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1932-7. PubMed ID: 15961700 [TBL] [Abstract][Full Text] [Related]
12. Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. Handattu SP; Datta G; Epand RM; Epand RF; Palgunachari MN; Mishra VK; Monroe CE; Keenum TD; Chaddha M; Anantharamaiah GM; Garber DW J Lipid Res; 2010 Dec; 51(12):3491-9. PubMed ID: 20841495 [TBL] [Abstract][Full Text] [Related]
13. Hydrogen decreases athero-susceptibility in apolipoprotein B-containing lipoproteins and aorta of apolipoprotein E knockout mice. Song G; Tian H; Qin S; Sun X; Yao S; Zong C; Luo Y; Liu J; Yu Y; Sang H; Wang X Atherosclerosis; 2012 Mar; 221(1):55-65. PubMed ID: 22209213 [TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E mimetics and cholesterol-lowering properties. Sharifov OF; Nayyar G; Garber DW; Handattu SP; Mishra VK; Goldberg D; Anantharamaiah GM; Gupta H Am J Cardiovasc Drugs; 2011 Dec; 11(6):371-81. PubMed ID: 22149316 [TBL] [Abstract][Full Text] [Related]
15. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Garber DW; Handattu S; Aslan I; Datta G; Chaddha M; Anantharamaiah GM Atherosclerosis; 2003 Jun; 168(2):229-37. PubMed ID: 12801605 [TBL] [Abstract][Full Text] [Related]
16. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. Navab M; Ruchala P; Waring AJ; Lehrer RI; Hama S; Hough G; Palgunachari MN; Anantharamaiah GM; Fogelman AM J Lipid Res; 2009 Aug; 50(8):1538-47. PubMed ID: 19225094 [TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function. Anantharamaiah GM; Garber DW; White CR Protein Pept Lett; 2016; 23(11):1024-1031. PubMed ID: 27586181 [TBL] [Abstract][Full Text] [Related]
18. Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice. Yakushiji E; Ayaori M; Nishida T; Shiotani K; Takiguchi S; Nakaya K; Uto-Kondo H; Ogura M; Sasaki M; Yogo M; Komatsu T; Lu R; Yokoyama S; Ikewaki K Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):591-7. PubMed ID: 26848156 [TBL] [Abstract][Full Text] [Related]
19. What does HDL do? A new mechanism to slow atherogenesis--but a new problem in type 2 diabetes mellitus. Williams KJ Atherosclerosis; 2012 Nov; 225(1):36-8. PubMed ID: 22770128 [No Abstract] [Full Text] [Related]